These 3 exercises may help with insomnia, new study finds
Low-intensity, low-impact exercise can improve sleep and ease the symptoms of insomnia, according to a new meta-analysis of 22 randomized clinical trials published Tuesday in the journal BMJ Evidence-Based Medicine.
The trials involved 13 non-pharmaceutical insomnia treatments, including seven fitness regimens, acupuncture, massage and cognitive behavioral therapy.
Among the exercises studied, yoga, tai chi, and walking or jogging showed the most promising evidence of helping participants fall asleep faster and stay asleep longer, with less awakenings.
'Growing evidence suggests that regular physical activity not only improves physical health, but also enhances sleep quality,' said Zhi-jun Bu, the study's first author and a doctoral student in clinical medicine at the Nanjing University of Chinese Medicine, in an email. 'However, most existing studies focus on just one type of exercise, lacking comprehensive comparisons.'
The research points to potential cost-effective, drug-free alternatives to traditional insomnia treatments, and further understanding the unique benefits of each exercise could be the next step, said Bu, who conducted the research when he was pursuing his master's degree at Beijing University of Chinese Medicine.
What causes insomnia, and how is it treated?
It's not unusual to struggle with frequent bouts of restlessness. About 14.5% of adults reported trouble falling asleep most days or every day in the past month, according to a 2020 survey by the US Centers for Disease Control and Prevention.
In a clinical setting, insomnia is generally diagnosed when someone has trouble falling asleep and experiences frequent, drawn-out sleep disruptions three times or more per week, said Dr. Shalini Paruthi, an adjunct professor of internal medicine and pediatrics at St. Louis University School of Medicine and spokesperson for the American Academy of Sleep Medicine.
Long-term insomnia can stem from a wide array of environmental and hereditary causes, including stress, poor sleep habits, chronic pain, medications or other sleep disorders such as sleep apnea, Paruthi said.
Typically, the first line of treatment for insomnia involves cognitive behavioral therapy, or CBT, a psychological approach aimed at adjusting patients' thoughts, feelings and behaviors around sleep.
'It's common (for patients with insomnia) to lose hope about getting sleep at night, to anticipate they're just going to lay in bed with a racing mind,' Paruthi said. 'CBT allows them to reconsider how they're approaching and thinking about sleep.'
Unlike other talk-oriented therapies, CBT does not require delving into a patient's past experiences or traumatic events, Paruthi said. Rather, the approach helps patients develop techniques to relax the mind and transition into sleep.
'We have very strong evidence that CBT can work just as good as medication, and it can last longer, because people are making new habits,' Paruthi said, adding that patients with insomnia typically see improvement in their symptoms after two to six weeks of therapy.
Exercise, on the other hand, is not considered a first-line treatment for insomnia in any clinical guidance literature. Still, Paruthi said she frequently recommends 150 minutes of moderate-intensity physical activity per week alongside other methods.
Important note: Before beginning any new exercise program, consult your doctor. Stop immediately if you experience pain.
Three exercises you could try for better sleep
Out of the randomized clinical trials Bu's team analyzed, these three physical activities had the best evidence behind their efficacy as a stand-alone treatment for insomnia.
Yoga: Two to six 45- to 60-minute sessions of yoga per week over one to four months increased total sleep duration by nearly two hours per night and reduced instances of waking after falling asleep by an hour.
'Yoga can promote better sleep by encouraging deep breathing, body awareness and a calm mental state, which helps reduce stress and anxiety — two common triggers of insomnia,' Bu suggested.
Tai chi: Two to three 45- to 60-minute sessions per week over three to four months increased total sleep duration by more than 50 minutes and reduced time spent awake by over 30 minutes.
The Chinese martial art involves combining a series of flowing, low-impact movement with deep, slow breathing that may help reduce stress and calm the body, Bu said.
Walking or jogging: Three to five 30- to 75-minute sessions per week over three to six months were shown to reduce symptoms of insomnia based on standardized scoring systems used in clinical settings.
'Walking or jogging improves sleep through both physical and emotional pathways: It increases energy expenditure, lowers stress hormones like cortisol, boosts mood, enhances melatonin production (the hormone that regulates sleep) and promotes deeper, more restorative sleep — ultimately helping to reduce insomnia symptoms,' Bu said.
A compelling case for exercise
Further research is needed to develop standardized regimens and understand the benefits of other exercises, Bu said. This information could help providers tailor their recommendations to the sleep challenges of their individual patients with insomnia.
While Paruthi said the evidence of the meta-analysis is a compelling case for exercise as a complementary treatment, she wouldn't routinely recommend it as the only remedy.
'If a patient wants to try exercising more, I say to start slow, build up that intensity and frequency over time, but listen to your body and observe how it is improving your sleep,' Paruthi said.
Timing your physical activity is important, too, she said. Exercise earlier in the day can make you feel alert, but an intense workout right before bed could make it harder to fall asleep.
'The most important thing is to choose something sustainable. … Sometimes it's easy to set lofty goals,' Paruthi said. '(With patients) we discuss what are some exercises they can routinely do and really stick to.'
If lifestyle changes alone aren't doing the trick, it may be time to visit a sleep specialist, she said.
Sign up for CNN's Sleep, But Better newsletter series. Our seven-part guide has helpful hints to achieve better sleep.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Entrepreneur
an hour ago
- Entrepreneur
LISSUN Acquires Being Cares to Strengthen Family-Focused Mental Health Services with AI
As part of the acquisition, Being Cares' Co-founders Varun Gandhi and Abhishek Sharma will join LISSUN as Chief Product Officer and Chief Technology Officer respectively. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Mental health platform LISSUN has acquired US-based mental wellness company Being Cares in a move aimed at integrating advanced artificial intelligence into family-oriented mental healthcare. The acquisition brings together LISSUN's therapist-led services with Being Cares' intelligent mental health mapping model, enabling a comprehensive, tech-driven approach to care. Being Cares currently supports nearly one million users across the globe through an AI-based system that monitors over 40 mental health conditions. These include anxiety, depression, burnout, and parenting-related stress. The system analyses more than 2,500 causes and effects to offer personalised mental health insights. LISSUN plans to further adapt this model to address child-centric issues such as autism, ADHD, speech delays, and learning difficulties. As part of the acquisition, Being Cares' co-founders Varun Gandhi and Abhishek Sharma will join LISSUN as Chief Product Officer and Chief Technology Officer respectively. "This is not just an acquisition. It marks the beginning of a complete reimagining of how mental healthcare can support entire families," said Tarun Gupta, Co-founder of LISSUN. "With Being's AI and our clinical expertise, we are building a system that addresses families' concerns from the very first signs, offers digital guidance, and seamlessly transitions into in-person care when needed." Founded in 2021 by Krishna Veer Singh and Tarun Gupta, LISSUN operates a hybrid mental health model that spans psychiatry, rehabilitation, infertility and maternity support, and child development. Its child-focused initiative, Sunshine by LISSUN, launched in June 2023, provides developmental and behavioural therapy for children with neurodevelopmental disorders. To date, Sunshine has delivered more than 30,000 therapy hours and supported over 10,000 children across 20 centers. Varun Gandhi, CEO and Co-founder of Being Cares, added, "Joining LISSUN felt like coming home. Our goal was always to build an empathetic, intelligent assistant that families could trust. With LISSUN, we now have the infrastructure, therapists, and shared values to bring this dream to life." Looking ahead, LISSUN plans to expand the Sunshine network to over 200 centers within the next two to four years. The company also intends to deploy its AI assistant Ray across platforms such as WhatsApp to provide real-time, personalised support to parents navigating their child's mental health. The firm emphasised that while this acquisition is a significant step forward, it remains open to collaborating with early-stage mental health startups developing innovative solutions.


Business Wire
2 hours ago
- Business Wire
ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone ® Lispro (THDB0206 injection) in People with T2D
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the 'Company'), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces that its partner Tonghua Dongbao releases today positive topline results on the Phase 3 clinical trial on BioChaperone ® Lispro (THDB0206 injection), a novel Ultra-Rapid Insulin formulation. Conducted by Tonghua Dongbao, this Phase 3 study (NCT05834868) was approved by the Chinese Regulatory Authorities (CDE 1). The randomized, open, multicenter study evaluated the safety and efficacy of THDB0206 injection compared to Humalog ® in adults with Type 2 diabetes. Dr LENG Chunsheng, President of Tonghua Dongbao, said: " THDB0206 injection is a new generation of ultra-rapid insulin that has demonstrated benefits for improving blood glucose control of adults with Type 2 diabetes compared with the standard of care Humalog ®. Tonghua Dongbao is committed to continue to innovate in the treatment of diabetes and obesity." Olivier Soula, CEO and Co-Founder of Adocia, added: " We are thrilled to share the positive results obtained with BioChaperone ® Lispro on this Phase 3 clinical trial on people with Type 2 diabetes. Given the well-known challenges in showing clinical improvement in this population with a new prandial insulin, we are particularly delighted with these findings. This milestone demonstrates Adocia's ability to advance its innovative treatments to the final stages of clinical development, within strategic partnerships. We congratulate Tonghua Dongbao's team for the quality of execution of a large Phase 3 trial of over 1,000 people.' Results A total of 1,040 Chinese adults with Type 2 diabetes with inadequate glycemic control and using daily multiple injections of insulin were randomized. After 26 weeks of treatment, HbA1c decreased significantly in both groups compared to the baseline. The reduction in the THDB0206 injection group was comparable to that of the Humalog ® group, meeting the primary endpoint. The key secondary endpoints were also demonstrated, with a statistically significant lower rise of blood glucose after a standard meal for the THDB0206 injection group, compared to the Humalog ® group. The 10-point self-monitoring blood glucose (SMBG) of patients at week 26, an important supportive endpoint of the trial, confirmed the advantage of this product in controlling postprandial blood glucose fluctuations, with a statistically improved daily blood glucose level. A series of prespecified subgroup analyzes of the primary HbA1c endpoint also fully confirmed the benefits of this product in long-term blood glucose control in patients with Type 2 diabetes. In addition, the safety and tolerability of THDB0206 injection were good. Most of the adverse events were mild or moderate, and the incidence of adverse events and hypoglycemic events were similar to those of Humalog ®. About BioChaperone ® Lispro BioChaperone ® Lispro was licensed to Tonghua Dongbao in 2018, as part of a Licensing Agreement covering China and other Asian countries 2. BioChaperone ® Lispro is an Ultra-Rapid Insulin, belonging to the latest generation of prandial insulins. It combines Adocia's proprietary BioChaperone ® technology with insulin lispro, the active ingredient in the standard of care, Humalog ® (Eli Lilly). This innovative formulation acts significantly faster than earlier insulin generations, effectively reducing post-meal hyperglycemia, which is a key contributor to long-term complications such as retinopathy, diabetic foot ulcers, or kidney failure. Additionally, its rapid elimination minimizes the risk of hypoglycemia, often caused when insulin level remains high after post-meal glucose levels have normalized. The faster action profile of BioChaperone ® Lispro associated to an excellent local tolerance enhances its compatibility with modern diabetes management systems, particularly insulin pump systems, and provides better integration into advanced treatment algorithms. Beyond its clinical advantages, the quick onset of BioChaperone ® Lispro improves quality of life by offering greater flexibility in dose timing. Patients can administer insulin at mealtime, or even right-after-mealtime, allowing for more accurate dosing based on known meal timing and content. This reduces the risks of overdosing or underdosing, which can lead to hypo- or hyperglycemia and their associated complications. The simplified dosing process eases the psychological burden on patients and caregivers, significantly alleviating the stress associated with diabetes management. About Tonghua Dongbao Tonghua Dongbao Pharmaceutical Co. Ltd (SHSE: 600867), is a pharmaceutical company based in Jilin province, China, specializing in the R&D, manufacturing and commercialization of insulins and other diabetes treatments. Tonghua Dongbao currently employs over 3,000 people and has sales of around $280 million. It has been listed on the Shanghai Stock Exchange since 1994, with a market capitalization of about $2.3 billion. About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone ® technology for the development of new generation insulins and products combining different hormones; 2) AdOral ®, an oral peptide delivery technology; 3) AdoShell ®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel ®, a long-acting drug delivery platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext ™ Paris (Euronext: ADOC; ISIN: FR0011184241). Disclaimer This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those set forth in the 'Risk Factors' section of the universal registration document that was filed with the French Autorité des marchés financiers on April 29, 2025, available at Those risks include uncertainties inherent in Adocia's short- or medium-term working capital requirements, in research and development, future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short-term financing requirements and its ability to raise additional funds.


Business Upturn
9 hours ago
- Business Upturn
Craig Harper Fights Cancer with Single-Digit Body Fat and a 'Be Savage' Mindset on Health is a Skill with Todd Vande Hei
By GlobeNewswire Published on July 25, 2025, 02:56 IST Beverly Hills California, July 24, 2025 (GLOBE NEWSWIRE) — In an episode that redefines resilience, Todd Vande Hei, CEO of Stark and host of Health is a Skill , sits down with 61-year-old executive Craig Harper to explore how deliberate health optimization can become a powerful edge against disease. Diagnosed with multiple myeloma, an incurable blood cancer, Harper was told by his first oncologist there was 'nothing he could do.' Instead, he chose to rewrite the script. 'I'd rather be a warrior in a garden than a gardener in a war,' Harper said. Instead of waiting passively for chemo, he doubled down on proactive labs, heavy lifting, and long weighted walks. Today, he maintains just 9% body fat, logs 15,000 steps daily in a 40-pound vest, and surfs whenever possible, remarkably with no current symptoms. Highlights from their conversation included: Why Stark's routine lab work caught his cancer early, enabling a critical head start on intervention. How building lean mass and metabolic flexibility became essential tools, with muscle acting as 'storage for sugar'—helping to undercut cancer's fuel. The role of sauna, nasal breathing, and mobility in keeping him hiking strenuous trails and popping up on a surfboard at 61. Teaching his grandkids to 'be savage, not average,' encouraging them to find and test their own edges in life. Reflecting on the typical American path, Harper added, 'So many of my counterparts just seek comfort, too much alcohol, junk food, the couch. It seems like pleasure, but it leads to misery.' Instead, he hopes his story inspires others to take control before a diagnosis forces the issue. 'When the old man's knocking, don't let him in,' he advised. Listeners can hear the full episode on Spotify, Apple Podcasts, and YouTube. To explore how personalized strength, nutrition, and lab analysis can help build a more resilient body, visit About Health Is a Skill Health is a Skill is a Los Angeles-based podcast hosted by Todd Vande Hei, CEO of Stark. Each episode blends scientific insight, personal stories, and actionable habits to show how optimizing healthspan can transform every decade of life. Media Communications [email protected] Attachment Craig Harper shares how he's out-training blood cancer with Todd Vande Hei on Health is a Skill. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.